| abstract |
The present invention relates to compositions using at least one poorly water-soluble statin (eg, simvastatin and / or lovastatin) and their use in treating, preventing and / or managing one or more cardiovascular diseases. About how to use. One method of the present invention delays the release of poorly water-soluble statins for a time sufficient to avoid metabolism of statins at or near the gastrointestinal wall by the cytochrome P450 3A metabolic system and This involves release of this statin in the ileum, colon or both, with subsequent uptake and distribution to hepatocytes, where HMG-CoA reductase activity can be inhibited with minimal adverse drug interactions. |